Clinical Trials Logo

Filter by:
NCT ID: NCT04767009 Recruiting - NSCLC Stage IV Clinical Trials

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Despite the impressive response rate to PD-1/PD-L1 immune checkpoint inhibitors, resistance inevitably develops in most patients. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors.

NCT ID: NCT04766827 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Start date: December 12, 2020
Phase: Phase 4
Study type: Interventional

Research Topic: A prospective randomized controlled clinical study of albumin-bound paclitaxel combined with cisplatin (AP regimen) versus docetaxel combined with cisplatin (TP regimen) induced chemotherapy in advanced head and neck squamous cell carcinoma Expected study duration: Each subject received a 3-week regimen of AP or TP over 2 cycles. Research objectives: To evaluate the efficacy and safety of induction chemotherapy with albumin-bound paclitaxel in patients with advanced head and neck squamous cell carcinoma (HSCC), two induction chemotherapy regimens, AP regimen and TP regimen, were compared. Trial Design. Single center, open label, controlled clinical study Number of cases: 116 Objective response rate (ORR=CR+PR) was used as the main evaluation index in this study.

NCT ID: NCT04766762 Recruiting - Clinical trials for Migraine Without Aura

A Randomized Controlled Trial of Acupuncture in Treating Migraine

Start date: April 21, 2021
Phase: N/A
Study type: Interventional

Migraine without aura is a common kind of nervous system diseases that can easily cause recurrent headache, leading to severe impacts on quality of life and health care costs. Current therapeutic options for migraine without aura mainly include flunarizine hydrochloride that can relieve vasospasm. Nevertheless, the efficacy of flunarizine hydrochloride is always limited by inevitable side effects, which result in poor compliance of patients. Moreover, for some most suffering patients, the control of pain is often unsatisfactory despite of the administration of complex treatment combinations. As a non-pharmaceutical therapy, acupuncture is widely used for a wide range of pain conditions. Thus, it might be an alternative treatment for migraine without aura. The aim of this randomized controlled trial is to investigate the efficacy and safety of acupuncture therapy in patients with migraine without aura from the perspective of Regulating Ying and Wei.

NCT ID: NCT04766515 Recruiting - Cancer Clinical Trials

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Start date: September 1, 2020
Phase:
Study type: Observational

This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

NCT ID: NCT04766320 Recruiting - Gynecologic Cancer Clinical Trials

Study on TIL for the Treatment of r/r Gynecologic Tumors

Start date: January 4, 2021
Phase: Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gynecologic tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.

NCT ID: NCT04766307 Recruiting - Clinical trials for Tuberculosis, Pulmonary

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Start date: July 20, 2016
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.

NCT ID: NCT04765462 Recruiting - Clinical trials for Malignant Solid Tumours

Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study is to determine the safety, feasibility and efficacy of allogeneic γδ T cell therapy in patients with solid tumors.

NCT ID: NCT04765228 Recruiting - Clinical trials for Stage III Adult Soft Tissue Sarcoma

Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for neoadjuvant treatment of locally advanced soft tissue sarcoma.

NCT ID: NCT04764513 Recruiting - Lymphoma Clinical Trials

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Start date: September 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates the infusion safety and potential curative properties of ex-vivo expanded γδ T cells obtained from the same donor for patients who have hematological malignancies and have accepted allogeneic hematopoietic stem cell transplantation.

NCT ID: NCT04764149 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma

Start date: November 1, 2019
Phase:
Study type: Observational

Local control rates of nasopharyngeal carcinoma are increasing, but 15% of patients still have local recurrence within 5 years after initial treatment. Systematic treatment based on chemotherapy has become the mainstream approach for recurrent nasopharyngeal carcinoma which is intolerant to local therapy. we sought to find an efficient chemotherapy regimen with high tolerance according to the characteristics of chemotherapy drugs, that is, to explore the efficacy and safety of platinum plus 5-fluorouracil with continuous intravenous infusion at a low dose for a long term.